Royalty Pharma (RPRX) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary

Portfolio performance and pipeline outlook

• Consistent annual addition of 8–10 new assets, with over 30 added since IPO in 2020, driving portfolio growth and outperformance, especially from products like Tremfya and Trikafta.

• Recent investments include Voranigo for low-grade glioma and synthetic royalties in products like Rytelo, Niktimvo, and Yorvipath, with several launches expected in the coming year.

• Pipeline includes royalties on first-in-class Lp(a) therapies (pelacarsen, olpasiran) with key data and launches expected in 2025–2026, and a Sanofi CD40 asset with phase II data for MS anticipated by 2027–2028.

• Aggregate sales from new pipeline assets (Lp(a), Sanofi, Cytokinetics, Geron, Syndax, Ascendis) are estimated at over $1 billion, with consensus estimates for the pipeline at $1.2 billion.

Vertex royalty dynamics and legal considerations

• Vertex royalties generated mid-$700 million last year, expected to grow to over $900 million under status quo, but could face a $200–$300 million headwind if royalty rates are reduced due to legal outcomes.

• Even in a worst-case scenario, royalties would not drop to zero, with a lower bound of $600–$700 million if 50–75% of patients switch to a new triple therapy.

• Arbitration is the contractually defined dispute resolution mechanism for the Vertex royalty issue, with an expedited process compared to court litigation.

Market and competitive landscape for key pipeline assets

• Lp(a) therapies are expected to see strong cardiologist interest and adoption, with the market not viewed as winner-take-all due to differences in administration (injectable vs. oral) and patient preferences.

• Cytokinetics' aficamten launch is modeled on the assumption that the company will self-launch, with expectations of a REMS program similar to Bristol's Camzyos, and no change in estimates if not acquired.